News

The new COVID-19 variant, B.1.1.7, continues to make its way around Europe and the world with new cases.

Biologics have become a novel treatment in recurrent C. difficile.

Since late 2004, 7 novel antibiotics with activity against ESBL-E, CRE, and/or DTR P aeruginosa have been approved.

A new study from Italy provides evidence that new mothers with COVID-19 can safely breastfeed and stay together in the same room with their newborns after delivery if they follow safety precautions.

Vaccine manufacturer Valneva recently announced it was initiating a phase 1/2 trial in the United Kingdom.

Anti-COVID-19 nanobodies may potentially be effective at preventing and diagnosing infections.

Phase 3 trial data shows experimental monoclonal antibody not to be efficacious.

While ACE2 expression has been reported in the human brain, the cell-specific expression pattern of ACE2 is unknown.

The agreement could mean upwards of 70 million more doses for eligible patients in mid-2021.

Characterizing SARS-CoV-2 interactions can improve understanding of viral RNA functions and the host innate immune response.

Regional and national decision-making can be informed by the online model, called the COVID-19 Pool Tool.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

The study helps to illuminate how spike proteins initiate infections.

Fostemsavir, an HIV-1 attachment inhibitor, is a novel therapeutic option for multidrug-resistant HIV. It represents the first oral agent developed for this indication in over a decade and provides promise for patients with limited remaining treatment options.

An Orphan Drug Designation was granted to Ridgeback Biotherapeutics, LP, creator the therapy.

Countries across Europe are reinstating travel bans and lockdowns to combat virus.

A new case series report highlights the unique circumstances of infant illness associated with COVID-19.

New data suggests informed, practical pooled testing could improve both public health response and clinical assessment of the pandemic.

Healthcare providers may want to consider these risks when determining which COVID-19 patients could benefit the most from the new monoclonal antibody therapies.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

The CDC stressed that antimicrobial stewardship remains a major public health concern.

The authors note that the difference in hospitalization rate may be partly due to existing immunity to influenza in the population.

Investigators in Tennessee detailed associations between seasonal increases in sporadic pediatric cases of norovirus gastroenteritis and reported norovirus outbreaks among older populations.

Regimen reduces mortality and recovery time in patients severely ill with pneumonia caused by the virus.